Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables: 2022-2025

Historic Receivables for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Sep 2025 value amounting to $32,000.

  • Corvus Pharmaceuticals' Receivables fell 77.14% to $32,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $272,000, marking a year-over-year decrease of 13.38%. This contributed to the annual value of $75,000 for FY2024, which is 44.23% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Receivables stood at $32,000, which was down 62.79% from $86,000 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Receivables' 5-year high stood at $1.2 million during Q4 2022, with a 5-year trough of $11,000 in Q3 2023.
  • In the last 3 years, Corvus Pharmaceuticals' Receivables had a median value of $70,000 in 2024 and averaged $66,333.
  • In the last 5 years, Corvus Pharmaceuticals' Receivables tumbled by 95.58% in 2023 and then surged by 1,172.73% in 2024.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Receivables stood at $1.2 million in 2022, then plummeted by 95.58% to $52,000 in 2023, then spiked by 44.23% to $75,000 in 2024, then slumped by 77.14% to $32,000 in 2025.
  • Its Receivables was $32,000 in Q3 2025, compared to $86,000 in Q2 2025 and $79,000 in Q1 2025.